Unknown

Dataset Information

0

Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I2-Imidazoline Receptor Ligand MCR5.


ABSTRACT: Behavioural and psychological symptoms of dementia (BPSD), including fear-anxiety- and depressive-like behaviour, are present in Alzheimer's disease (AD), together with memory decline. I2-imidazoline receptors (I2-IRs) have been associated with neuropsychiatric and neurodegenerative disorders, further, I2-IR ligands have demonstrated a neuroprotective role in the central nervous system (CNS). In this study, we assessed the effect of the I2-IR ligand MCR5 on both cognitive and non-cognitive symptoms in the Senescence accelerated mice prone 8 (SAMP8) mouse model. Oral administration of I2-IR ligand MCR5 (5 mg/kg/day for four weeks) in 10-month SAMP8 mice ameliorated both BPSD-like phenotype and cognitive decline by attenuating depressive-like behaviour, reducing fear-anxiety-like behaviour and improving cognitive performance using different tasks. Interaction of I2-IR ligand MCR5 with serotoninergic system did not account for behavioural or cognitive improvement, although changes in molecular pathways underlying depression and anxiety phenotype were observed. MCR5 increased levels of p-AKT, phosphorylated glycogen synthase kinase 3 ? (GSK3?) at Ser9 and phosphorylated mammalian target of rapamycin complex 1 (mTORC1) levels in SAMP8 treated mice compared to SAMP8 control. Moreover, MCR5 treatment altered N-methyl-d-aspartate receptor (NMDA) 2B phosphorylation, and decreased the protein levels of phosphorylated cyclin-dependent kinase 5 (p-CDK5) and dopamine- and cyclic adenosine monophosphate (cAMP)-regulated phosphoprotein of Mr 32 kDa phosphorylated at Thr75 (p-DARPP32), with a parallel increase in protein kinase A (PKA) and p-cAMP response element-binding (pCREB) levels. Consistent with these changes MCR5 attenuated neuroinflammation by decreasing expression of pro-inflammatory markers such as Tumor necrosis factor-alpha (Tnf-?), Interleukin 1? (Il-1?), Interleukin 6 (Il-6), and promoted synaptic plasticity by increasing levels of postsynaptic density protein 95 (PSD95) as well as ameliorating tropomyosin-related kinase B (TrkB) and nerve growth factor receptor (NGFR) signalling. Collectively, these results increase the potential of highly selective I2-IR ligands as therapeutic agents in age-related BPSD and cognitive alterations.

SUBMITTER: Vasilopoulou F 

PROVIDER: S-EPMC7285228 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I<sub>2</sub>-Imidazoline Receptor Ligand MCR5.

Vasilopoulou Foteini F   Bagan Andrea A   Rodriguez-Arevalo Sergio S   Escolano Carmen C   Griñán-Ferré Christian C   Pallàs Mercè M  

Pharmaceutics 20200523 5


Behavioural and psychological symptoms of dementia (BPSD), including fear-anxiety- and depressive-like behaviour, are present in Alzheimer's disease (AD), together with memory decline. I<sub>2</sub>-imidazoline receptors (I<sub>2</sub>-IRs) have been associated with neuropsychiatric and neurodegenerative disorders, further, I<sub>2</sub>-IR ligands have demonstrated a neuroprotective role in the central nervous system (CNS). In this study, we assessed the effect of the I<sub>2</sub>-IR ligand MC  ...[more]

Similar Datasets

| S-EPMC6554384 | biostudies-literature
| S-EPMC9406492 | biostudies-literature
| S-EPMC8110656 | biostudies-literature
| S-EPMC10298009 | biostudies-literature
| S-EPMC8419189 | biostudies-literature
| S-EPMC7411305 | biostudies-literature
| S-EPMC3929979 | biostudies-literature
| S-EPMC6953020 | biostudies-literature
| S-EPMC8425557 | biostudies-literature
| S-EPMC5400562 | biostudies-literature